A detailed history of Jane Street Group, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 121,593 shares of TERN stock, worth $701,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,593
Previous 143,332 15.17%
Holding current value
$701,591
Previous $976,000 3.89%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $141,086 - $234,781
-21,739 Reduced 15.17%
121,593 $1.01 Million
Q2 2024

Aug 14, 2024

BUY
$4.54 - $8.2 $434,387 - $784,575
95,680 Added 200.79%
143,332 $976,000
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $81,652 - $137,600
-16,801 Reduced 26.07%
47,652 $312,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $6.86 $217,206 - $442,147
64,453 New
64,453 $418,000
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.29 $920,095 - $1.66 Million
-125,183 Reduced 83.81%
24,178 $211,000
Q1 2023

May 15, 2023

BUY
$7.91 - $12.0 $1.01 Million - $1.53 Million
127,854 Added 594.48%
149,361 $1.77 Million
Q4 2022

Feb 14, 2023

BUY
$4.62 - $10.18 $38,124 - $84,005
8,252 Added 62.26%
21,507 $218,000
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $24,786 - $85,097
13,255 New
13,255 $78,000
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $24,786 - $85,097
13,255 New
13,255 $78,000
Q3 2021

Nov 16, 2021

SELL
$7.22 - $13.46 $86,445 - $161,156
-11,973 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$12.26 - $22.0 $146,788 - $263,406
11,973 New
11,973 $147,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $217M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.